To examine whether a possible pharmacological augmentation of Erf localization in vivo could affect the craniosynostosis phenotype, we treated ErfloxP/+ and ErfloxP/− littermates with U0126, KPT-330 or 50% DMSO carrier solution on alternate days from P5 to P65. The gene discussed is ERF; the disease is craniosynostosis.